Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.4% – What’s Next?

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) traded down 3.4% on Friday . The stock traded as low as $15.88 and last traded at $15.73. 16,371 shares were traded during mid-day trading, a decline of 97% from the average session volume of 469,299 shares. The stock had previously closed at $16.28.

Analyst Ratings Changes

Several equities analysts have recently commented on CNTA shares. Guggenheim lifted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Stock Up 1.1 %

The company has a market cap of $2.17 billion, a price-to-earnings ratio of -10.76 and a beta of 1.53. The stock has a 50-day simple moving average of $16.79 and a 200-day simple moving average of $14.88. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16. Following the completion of the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $10,626,702.06. This trade represents a 13.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Karen M. Anderson sold 5,876 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $17.01, for a total value of $99,950.76. Following the completion of the sale, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $1,216,640.25. This represents a 7.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 392,484 shares of company stock valued at $6,723,523 in the last three months. 11.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $148,000. Fred Alger Management LLC acquired a new stake in Centessa Pharmaceuticals in the second quarter valued at approximately $99,000. The Manufacturers Life Insurance Company grew its position in Centessa Pharmaceuticals by 30.4% in the second quarter. The Manufacturers Life Insurance Company now owns 140,894 shares of the company’s stock worth $1,272,000 after acquiring an additional 32,846 shares in the last quarter. Driehaus Capital Management LLC increased its stake in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after purchasing an additional 987,997 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.